CLINICAL TRIALS PROFILE FOR PARSABIV
✉ Email this page to a colleague
All Clinical Trials for PARSABIV
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02833857 ↗ | A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis | Completed | Amgen | Phase 1 | 2017-03-14 | This is a study to evaluate the safety and pharmacokinetics in pediatric patients with secondary hyperparathyroidism receiving a single dose of etelcalcetide at the end of hemodialysis. |
| NCT03633708 ↗ | Study of Etelcalceide in Pediatric Subjects With Secondary Hyperparathyroidism and CKD on Hemodialysis | Recruiting | Amgen | Phase 3 | 2019-04-29 | Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis |
| NCT03795558 ↗ | A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients | Active, not recruiting | Amgen | Phase 2 | 2019-05-01 | This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal disease patients on chronic hemodialysis with secondary hyperparathyroidism. |
| NCT03795558 ↗ | A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients | Active, not recruiting | Prim. Priv. Doz. Dr. Daniel Cejka | Phase 2 | 2019-05-01 | This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal disease patients on chronic hemodialysis with secondary hyperparathyroidism. |
| NCT03960437 ↗ | The Effect of Etelcalcetide on CKD-MBD | Recruiting | Thomas Nickolas, MD MS | Phase 2 | 2018-09-06 | The proposed study will investigate the effects of etelcalcetide on the bone and blood-vessel health in patients with CKD-MBD. The investigators will test if etelcalcetide makes bone and blood-vessels healthier. The study hypotheses are that are that etelcalcetide keeps bones strong and lowers the risk of calcium deposits in blood vessels. In Aim 1, the investigators will test if 9-months of treatment with etelcalcetide improves bone strength in twenty ESKD patients with hyperparathyroidism (HPT) by bone biopsy. In Aim 2, the investigators will test if 9-months of treatment with etelcalcetide decreases serum propensity to calcify blood vessels. The potential significance of this study is to provide first-time data on the ability of etelcalcetide to protect bone and blood-vessel health in patients with ESKD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PARSABIV
Condition Name
Clinical Trial Locations for PARSABIV
Trials by Country
Clinical Trial Progress for PARSABIV
Clinical Trial Phase
Clinical Trial Sponsors for PARSABIV
Sponsor Name
